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H.pylori chronic infection can cause chronic gastritis 
and atrophic gastritis that leads to adenocarcinoma of 
gaster. Eradication of H.pylori has shown to decrease 
the risk of gastric cancer. An integral part of H.pylori 
eradication is acid blocker. The addition of proton 
SXPSLQKLELWRU33,KDVSURYHQVLJQL¿FDQWO\LQFUHDVH
the eradication rate. Combination of acid suppresion 
and antibiotics is currently the standard treatment for 
H.pylori eradication. Acid blocker has been proved 
to decrease urease activity, increased stability and 
effectivity of antibiotics.
The decreasing rate of eradication in some areas in 
Japan led to many trials try to make higher eradication 
rate by changing the antibiotic regimen until recently 
some report focused on higher acid blocker capacity 
drug. Pioneer studies come from Japan in 2014 with 
the invention of new acid blocker Vonoprazan.1
Vonoprazan is a potassium competitive acid blocker 
(PCAB). PCAB is more potent acid suppressive agent 
compare to conventional PPI. PCAB also has the 
EHQH¿W RI UDSLG DQGPRUH VXVWDLQHG DFLG LQKLELWRU\
effect. This unique properties of vonoprazan should 
SURYLGHJUHDWHUHI¿FDF\LQH.pylori infection.
Kajihara study shows eradication rate using 
vonoprazan more than 95%. Previous studies in 
Japan show the rate of eradication using vonoprazan 
cased therapy range from 87-92 % higher compare 
to PPI based regimens (66-75%).2,3,4,5,6 These studies 
have shown increase in H.pylori eradication rate with 
vonoprazan even with standard antibiotics regimens 
hypothetically caused by better acid control. Study 
E\.DMLKDUD VKRZQR GLIIHUHQW LQ HI¿FDF\ EHWZHHQ
male and female, although female experienced more 
adverse events.6
9RQRSUD]DQ EDVHG WKHUDS\ HI¿FDF\ QHHGV WR EH
studied more in other region outside Japan to prove 
its superiority compare to conventional PPI and to 
evaluate the adverse events. 
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